Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camidanlumab Tesirine in Relapsed/Refractory Hodgkin Lymphoma
NCT04052997Phase 2Completed
- Sponsor
- ADC Therapeutics
- Start
- Sep 2019
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 11
01
Overview
A Phase 2 trial of camidanlumab tesirine in Hodgkin lymphoma (HL), sponsored by ADC Therapeutics. Started Sep 2019; status: completed.
02
Drugs
camidanlumab tesirine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT04052997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04052997.